Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.51 |
| ▸ | HPGD | P15428 | 5/20 | 0.51 |
| ▸ | LMNA | P02545 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.50 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | NUDT1 | P36639 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | TSPO | P30536 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3089782 | 0.92 | ADORA3 (0.49) | ADORA3ALDH1A1HPGDLMNAHSP90AA1 | |
| SCHEMBL13144396 | 0.91 | ADORA3 (0.48) | ADORA3ALDH1A1HPGDLMNAHSP90AA1 | |
| SCHEMBL3093854 | 0.91 | TSHR (0.49) | ADORA3LMNA | |
| SCHEMBL13144440 | 0.90 | ADORA3 (0.47) | ADORA3ALDH1A1HPGDLMNAHSP90AA1 | |
| SCHEMBL13144391 | 0.88 | HSP90AA1 (0.46) | ADORA3ALDH1A1HPGDLMNAHSP90AA1 | |
| SCHEMBL3087920 | 0.87 | ADORA3 (0.52) | ADORA3ALDH1A1HPGDHSP90AA1HSP90AB1 | |
| SCHEMBL3089581 | 0.84 | HPGD (0.50) | ALDH1A1HPGDLMNAHSP90AA1TSPO | |
| SCHEMBL3096899 | 0.83 | ADORA3 (0.49) | ADORA3ALDH1A1HPGDHSP90AA1HSP90AB1 | |
| SCHEMBL3075153 | 0.83 | ADORA3 (0.57) | ADORA3ALDH1A1HPGDLMNAHSP90AA1 | |
| SCHEMBL13144387 | 0.82 | ADORA3 (0.52) | ADORA3ALDH1A1HPGDHSP90AA1HSP90AB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | claimed |
| US-8501754-B2 | Quinazolinamide derivatives | MERCK PATENT GMBH (DE) | 2013-08-06 | — | — | US | claimed |
| US-20100234324-A1 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 2010-09-16 | — | — | US | claimed |
| EP-2164833-B1 | Quinazolinamide derivatives useful for the treatment of tumour diseases | MERCK PATENT GMBH (DE) | 2015-04-15 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100234324-A1 | Quinazolinamide derivatives | HSP90AB1, HSP90AA1, HSP90AB2P | ADORA3 3301/4885ALDH1A1 1776/4885HPGD 574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.